CVS beats estimates, hikes guidance as insurance business improves

CVS Health reported third-quarter adjusted earnings of $1.60 per share and revenue of $102.87 billion, both exceeding analyst expectations, and subsequently raised its fiscal 2025 adjusted profit outlook for the third consecutive quarter. This strong operational performance was driven by improvements in its Aetna insurance unit and robust sales at its Caremark pharmacy benefit manager. However, the company posted a net loss of $3.99 billion due to a $5.7 billion goodwill impairment charge related to its health care delivery segment, which led to a premarket stock decline despite the positive top-line results and raised guidance, indicating investor concern over strategic adjustments in that unit, including slowing clinic growth and closing underperforming Oak Street Health locations.

Analysis

CVS Health reported robust third-quarter results, significantly surpassing analyst expectations with adjusted EPS of $1.60 against an anticipated $1.37 and revenue of $102.87 billion, exceeding the $98.85 billion forecast. The company also raised its fiscal 2025 adjusted profit outlook for the third consecutive quarter, now projecting $6.55-$6.65 per share. Despite these strong operational beats and positive guidance, CVS shares declined over 3% premarket, primarily due to a reported net loss of $3.99 billion.

This net loss stemmed from a substantial $5.7 billion goodwill impairment charge related to the health care services segment's health care delivery unit. Operational strength was driven by significant improvements in the Aetna insurance unit, with its medical benefit ratio decreasing to 92.8% and a 9% revenue increase to $35.99 billion, largely from its government business. The pharmacy and consumer wellness division grew 11.7% to $36.21 billion, and the health services segment posted an 11.6% revenue increase to $49.27 billion.

The impairment charge reflects challenges in the health care delivery unit's growth trajectory, leading CVS to implement strategic adjustments. These include slowing primary care clinic expansion and closing 16 underperforming Oak Street Health locations. While CEO Joyner affirmed commitment to value-based care, these actions signal a recalibration of growth expectations within this specific segment.

Key Decisions for Investors

• Investors should carefully weigh the strong core business performance and raised guidance against the significant goodwill impairment and strategic recalibration in the health care delivery segment.
• Monitor the execution and impact of CVS's revised strategy for its health care delivery unit, particularly the performance of remaining clinics and future growth projections, as this unit has faced growth challenges.
• Consider the sustained positive momentum in the Aetna insurance unit and Caremark PBM, which continue to drive revenue beats and improved profitability, as key long-term value drivers.